

2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

St. Louis, MO – February 22, 2020

**Conference
Location**

Renaissance St Louis Airport

Phone: 314 429-1100

9801 Natural Bridge Road,
St. Louis, MO 63134

<https://www.marriott.com/hotels/travel/stlsa-renaissance-st-louis-airport-hotel/>

**Parking at the
Conference**

Complimentary Parking for all participants is included as part of the program.

Driving Directions

From Downtown St Louis

- Take I-64 W/US-40 W
- Take exit 31A for Interstate 170 N toward Airport
- Continue onto I-170 N
- Take exit 6 for MO-115/Natural Bridge Rd
- Turn left onto MO-115 W/Natural Bridge Rd
- Continue to 9802 Natural Bridge Rd,

**Seminar Agenda
and Syllabus
Information**

Registration and breakfast begin at **7:30 a.m.** in the **Gatwick Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:25 am	Hepatocellular Carcinoma (HCC) • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis • Epidemiology of PSC and Ursodiol and Antibiotic Treatments

	- Predicting outcomes and Improving Survival in PSC patients - Causes and Markers of PBC - Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
11:40 am	Hepatology Update I – Viral Hepatitis The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs
12:15 pm	Luncheon Presentation
12:55pm	Dessert and View Exhibits
1:10pm	Hepatology Update II Emerging Topics in Liver Disease Alcoholic Liver Disease, Liver disease and Pregnancy, Hepatorenal syndrome
1:40 pm	NAFLD, LAL-D and NASH - Epidemiology, Demographics and Diagnosis - Treatment options for thrombocytopenia; including alternatives to platelet transfusion. - Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	Break & View Exhibits
2:30 pm	NASH Treatments in Practice and in Development - Current therapies for NASH - Life style changes as a therapy - Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:30 pm	Post-test and Wrap-Up

Attendance Policies

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is **received in writing no later than seven days prior** to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for **7.3 continuing education credits** through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your Seminar
Faculty**



BRUCE BACON, MD

Bruce R. Bacon, M.D. is Professor of Internal Medicine, and the inaugural holder of the James F. King, MD Endowed Chair in Gastroenterology at Saint Louis University. He was the Director of the Division of Gastroenterology & Hepatology from 1990 to 2010 and was the Co-Director of the Abdominal Transplant Program at Saint Louis University Hospital from 2012 to 2017. He is currently the Co-Director of the Saint Louis University Liver Center.

Dr. Bacon is a former President of the American Association for the Study of Liver Diseases (AASLD) in 2004 and he received the Distinguished Service Award from the AASLD in 2010. Dr. Bacon has been the Chair of the AASLD Foundation since 2013. He is the former Chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine and the former Chair of the Subspecialty Board on Transplant Hepatology for the ABIM.



MAURICIO LISKER-MELMAN, MD

Dr. Lisker-Melman is Professor of Medicine and Director of the Hepatology Program in the Division of Gastroenterology at Washington University School of Medicine (WUSM). He has worked at WUSM since 2000. He received his M.D. from the National Autonomous University of Mexico (UNAM) in 1980, and completed his training in internal medicine and gastroenterology at the Instituto Nacional de la Nutrición Salvador Zubiran (INNSZ) in Mexico City (1980-85). He is a Founder member of the Mexican Liver Foundation. Dr. Lisker-Melman has held various positions on the Governing Boards of the Mexican Association of Internal Medicine, Mexican Board of Gastroenterology, Mexican Association of Hepatology, American Gastroenterological Association and American Liver Foundation.

His major clinical research interests involve the diagnosis and treatment of viral hepatitis and the complications associated with chronic viral hepatitis and end stage liver disease.



ALEXA FIDER-WHYTE, PA-C, DMSc

Alexa M. Fider-Whyte, PA-C is a board certified Physician Assistant at Saint Louis University. She received her undergraduate degree from Norfolk State University as a Dozoretz National Institute for Mathematics and Applied Sciences (DNIMAS) scholar. Additionally, she earned her Masters of Medical Science and Physician Assistant degree from Saint Louis University in 2004. In 2005, Alexa was awarded a 12 month clinical hepatology fellowship sponsored by the American Association for the Study of Liver Disease (AASLD) after which she completed an additional 6 months of training in transplant hepatology. She recently completed a Doctor of Medical Science (DMSc).

Alexa has been working alongside the Medical Director of the Liver Transplant for more than 13 years. Clinically, she specializes in general and transplant hepatology. She has expertise in abdominal paracentesis, management of chronic liver disease, management of cirrhosis, and management of patients in the post-transplant setting. Her area of clinical and research interest is that of sarcopenia and frailty in patients with cirrhosis and in the early post-transplant period. Professionally, she is an associate member of the American Association for the Study of Liver Disease.
